nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—SLCO3A1—nephron—focal segmental glomerulosclerosis	0.0882	0.266	CbGeAlD
Alprostadil—Joint dislocation—Cyclosporine—focal segmental glomerulosclerosis	0.0721	0.177	CcSEcCtD
Alprostadil—PTGIR—endothelium—focal segmental glomerulosclerosis	0.0471	0.142	CbGeAlD
Alprostadil—PTGER1—kidney—focal segmental glomerulosclerosis	0.0307	0.0926	CbGeAlD
Alprostadil—PTGIR—kidney—focal segmental glomerulosclerosis	0.0189	0.0572	CbGeAlD
Alprostadil—SLCO2A1—nephron tubule—focal segmental glomerulosclerosis	0.0188	0.0569	CbGeAlD
Alprostadil—Stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.0179	0.044	CcSEcCtD
Alprostadil—ABCC5—nephron tubule—focal segmental glomerulosclerosis	0.0172	0.052	CbGeAlD
Alprostadil—SLCO3A1—kidney—focal segmental glomerulosclerosis	0.0167	0.0505	CbGeAlD
Alprostadil—SLCO2A1—kidney—focal segmental glomerulosclerosis	0.0166	0.05	CbGeAlD
Alprostadil—SLCO2A1—Transport of organic anions—ALB—focal segmental glomerulosclerosis	0.0165	0.0628	CbGpPWpGaD
Alprostadil—SLCO3A1—cortex of kidney—focal segmental glomerulosclerosis	0.0163	0.0492	CbGeAlD
Alprostadil—SLCO2A1—cortex of kidney—focal segmental glomerulosclerosis	0.0161	0.0487	CbGeAlD
Alprostadil—SLCO3A1—Transport of organic anions—ALB—focal segmental glomerulosclerosis	0.0156	0.0596	CbGpPWpGaD
Alprostadil—Trauma—Cyclosporine—focal segmental glomerulosclerosis	0.0143	0.0351	CcSEcCtD
Alprostadil—Micturition urgency—Cyclosporine—focal segmental glomerulosclerosis	0.012	0.0295	CcSEcCtD
Alprostadil—ABCC4—nephron tubule—focal segmental glomerulosclerosis	0.0119	0.0361	CbGeAlD
Alprostadil—SLCO2B1—kidney—focal segmental glomerulosclerosis	0.0119	0.0358	CbGeAlD
Alprostadil—Hypertriglyceridaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0118	0.0291	CcSEcCtD
Alprostadil—Multiple fractures—Cyclosporine—focal segmental glomerulosclerosis	0.0117	0.0288	CcSEcCtD
Alprostadil—Fracture—Cyclosporine—focal segmental glomerulosclerosis	0.0117	0.0288	CcSEcCtD
Alprostadil—Serum creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.011	0.0272	CcSEcCtD
Alprostadil—ABCC4—kidney—focal segmental glomerulosclerosis	0.0105	0.0317	CbGeAlD
Alprostadil—PTGER2—Prostaglandin Synthesis and Regulation—EDN1—focal segmental glomerulosclerosis	0.0105	0.04	CbGpPWpGaD
Alprostadil—Blood triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.0104	0.0255	CcSEcCtD
Alprostadil—ABCC4—cortex of kidney—focal segmental glomerulosclerosis	0.0102	0.0309	CbGeAlD
Alprostadil—Burning sensation—Cyclosporine—focal segmental glomerulosclerosis	0.00978	0.0241	CcSEcCtD
Alprostadil—Influenza-like symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.00952	0.0234	CcSEcCtD
Alprostadil—SLCO2B1—Transport of organic anions—ALB—focal segmental glomerulosclerosis	0.00905	0.0345	CbGpPWpGaD
Alprostadil—Fungal infection—Cyclosporine—focal segmental glomerulosclerosis	0.0088	0.0216	CcSEcCtD
Alprostadil—Feeling hot—Cyclosporine—focal segmental glomerulosclerosis	0.00866	0.0213	CcSEcCtD
Alprostadil—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00758	0.0186	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00747	0.0184	CcSEcCtD
Alprostadil—PTGIR—Prostaglandin Synthesis and Regulation—EDN1—focal segmental glomerulosclerosis	0.00708	0.027	CbGpPWpGaD
Alprostadil—PTGER1—Prostaglandin Synthesis and Regulation—EDN1—focal segmental glomerulosclerosis	0.00708	0.027	CbGpPWpGaD
Alprostadil—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00668	0.0164	CcSEcCtD
Alprostadil—Influenza like illness—Cyclosporine—focal segmental glomerulosclerosis	0.0066	0.0162	CcSEcCtD
Alprostadil—PTGIR—Endothelin Pathways—EDN1—focal segmental glomerulosclerosis	0.00656	0.025	CbGpPWpGaD
Alprostadil—Cramps of lower extremities—Cyclosporine—focal segmental glomerulosclerosis	0.00624	0.0154	CcSEcCtD
Alprostadil—ABCC4—Platelet degranulation—ACTN4—focal segmental glomerulosclerosis	0.00619	0.0236	CbGpPWpGaD
Alprostadil—SLCO2A1—Transport of vitamins, nucleosides, and related molecules—ALB—focal segmental glomerulosclerosis	0.00611	0.0233	CbGpPWpGaD
Alprostadil—Abnormal vision—Cyclosporine—focal segmental glomerulosclerosis	0.00593	0.0146	CcSEcCtD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—ACTN4—focal segmental glomerulosclerosis	0.0059	0.0225	CbGpPWpGaD
Alprostadil—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.0059	0.0145	CcSEcCtD
Alprostadil—SLCO3A1—Transport of vitamins, nucleosides, and related molecules—ALB—focal segmental glomerulosclerosis	0.00579	0.0221	CbGpPWpGaD
Alprostadil—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00567	0.0139	CcSEcCtD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—GNAQ—focal segmental glomerulosclerosis	0.00554	0.0211	CbGpPWpGaD
Alprostadil—Injury—Cyclosporine—focal segmental glomerulosclerosis	0.00537	0.0132	CcSEcCtD
Alprostadil—ABCC4—Ectoderm Differentiation—PODXL—focal segmental glomerulosclerosis	0.0051	0.0195	CbGpPWpGaD
Alprostadil—PTGIR—Platelet homeostasis—TRPC6—focal segmental glomerulosclerosis	0.00509	0.0194	CbGpPWpGaD
Alprostadil—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00506	0.0124	CcSEcCtD
Alprostadil—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00503	0.0124	CcSEcCtD
Alprostadil—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00462	0.0114	CcSEcCtD
Alprostadil—Sweating increased—Cyclosporine—focal segmental glomerulosclerosis	0.00415	0.0102	CcSEcCtD
Alprostadil—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.0041	0.0101	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00396	0.00975	CcSEcCtD
Alprostadil—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00394	0.00969	CcSEcCtD
Alprostadil—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00385	0.00946	CcSEcCtD
Alprostadil—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00375	0.00922	CcSEcCtD
Alprostadil—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00374	0.00919	CcSEcCtD
Alprostadil—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00373	0.00917	CcSEcCtD
Alprostadil—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.0037	0.00909	CcSEcCtD
Alprostadil—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00363	0.00891	CcSEcCtD
Alprostadil—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00357	0.00877	CcSEcCtD
Alprostadil—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.00343	0.00844	CcSEcCtD
Alprostadil—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.00342	0.00841	CcSEcCtD
Alprostadil—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00341	0.00839	CcSEcCtD
Alprostadil—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.0034	0.00835	CcSEcCtD
Alprostadil—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.00339	0.00833	CcSEcCtD
Alprostadil—SLCO2B1—Transport of vitamins, nucleosides, and related molecules—ALB—focal segmental glomerulosclerosis	0.00336	0.0128	CbGpPWpGaD
Alprostadil—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00335	0.00823	CcSEcCtD
Alprostadil—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00329	0.00809	CcSEcCtD
Alprostadil—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.00317	0.00779	CcSEcCtD
Alprostadil—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00289	0.0071	CcSEcCtD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00287	0.011	CbGpPWpGaD
Alprostadil—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00286	0.00702	CcSEcCtD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	0.00275	0.0105	CbGpPWpGaD
Alprostadil—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00275	0.00675	CcSEcCtD
Alprostadil—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00259	0.00638	CcSEcCtD
Alprostadil—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.00257	0.00633	CcSEcCtD
Alprostadil—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00257	0.00631	CcSEcCtD
Alprostadil—PTGER1—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.00253	0.00964	CbGpPWpGaD
Alprostadil—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.0025	0.00615	CcSEcCtD
Alprostadil—PTGIR—Platelet homeostasis—NOS2—focal segmental glomerulosclerosis	0.0025	0.00953	CbGpPWpGaD
Alprostadil—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.00247	0.00608	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00246	0.0094	CbGpPWpGaD
Alprostadil—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.00242	0.00596	CcSEcCtD
Alprostadil—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00241	0.00592	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—ACTN4—focal segmental glomerulosclerosis	0.00238	0.00906	CbGpPWpGaD
Alprostadil—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00237	0.00584	CcSEcCtD
Alprostadil—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00236	0.00579	CcSEcCtD
Alprostadil—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.00234	0.00576	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.00226	0.00862	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00221	0.00843	CbGpPWpGaD
Alprostadil—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.00213	0.00525	CcSEcCtD
Alprostadil—PTGER1—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.00211	0.00806	CbGpPWpGaD
Alprostadil—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.00207	0.0051	CcSEcCtD
Alprostadil—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.002	0.00491	CcSEcCtD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00194	0.00741	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00194	0.00741	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.00193	0.00737	CbGpPWpGaD
Alprostadil—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00192	0.00471	CcSEcCtD
Alprostadil—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00192	0.00471	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00189	0.00722	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.00189	0.00721	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00188	0.00715	CbGpPWpGaD
Alprostadil—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00174	0.00428	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.00173	0.00659	CbGpPWpGaD
Alprostadil—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00172	0.00422	CcSEcCtD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00166	0.00635	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00166	0.00635	CbGpPWpGaD
Alprostadil—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00166	0.00408	CcSEcCtD
Alprostadil—PTGER1—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.00164	0.00625	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.00161	0.00616	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.00161	0.00612	CbGpPWpGaD
Alprostadil—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.0016	0.00394	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	0.00159	0.00607	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.00153	0.00584	CbGpPWpGaD
Alprostadil—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00153	0.00376	CcSEcCtD
Alprostadil—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00153	0.00376	CcSEcCtD
Alprostadil—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00152	0.00374	CcSEcCtD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00149	0.0057	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00149	0.0057	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—FN1—focal segmental glomerulosclerosis	0.00148	0.00563	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.00146	0.00559	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.00144	0.0055	CbGpPWpGaD
Alprostadil—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00144	0.00354	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—ACTN4—focal segmental glomerulosclerosis	0.00142	0.0054	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—FN1—focal segmental glomerulosclerosis	0.00141	0.00537	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.00136	0.00519	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.00133	0.00508	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	0.00132	0.00503	CbGpPWpGaD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	0.00131	0.005	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00128	0.00488	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00128	0.00488	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00127	0.00483	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00127	0.00483	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	0.00124	0.00474	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—SERPINE1—focal segmental glomerulosclerosis	0.00123	0.00469	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—ALB—focal segmental glomerulosclerosis	0.00123	0.00468	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.00122	0.00466	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.00122	0.00464	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—SERPINE1—focal segmental glomerulosclerosis	0.00117	0.00447	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—ALB—focal segmental glomerulosclerosis	0.00117	0.00446	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TRPC6—focal segmental glomerulosclerosis	0.00114	0.00435	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	0.0011	0.0042	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.00108	0.00414	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.00108	0.00414	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.00107	0.00407	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.00106	0.00404	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.00101	0.00387	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.001	0.00382	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000974	0.00372	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000974	0.00372	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000968	0.00369	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000963	0.00367	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—GNAQ—focal segmental glomerulosclerosis	0.000953	0.00363	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	0.000948	0.00362	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.00092	0.00351	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.0009	0.00343	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.0009	0.00343	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000891	0.0034	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000888	0.00339	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000848	0.00324	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000826	0.00315	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000826	0.00315	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000815	0.00311	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000809	0.00309	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000778	0.00297	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—TGFB1—focal segmental glomerulosclerosis	0.000776	0.00296	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.00074	0.00282	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—TGFB1—focal segmental glomerulosclerosis	0.000739	0.00282	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	0.000721	0.00275	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.00072	0.00275	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.00072	0.00275	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000716	0.00273	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000716	0.00273	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000692	0.00264	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000691	0.00264	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000686	0.00262	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000686	0.00262	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TRPC6—focal segmental glomerulosclerosis	0.000679	0.00259	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000677	0.00258	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000677	0.00258	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000667	0.00254	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	0.000655	0.0025	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000654	0.00249	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000654	0.00249	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.00065	0.00248	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.00065	0.00248	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000632	0.00241	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000627	0.00239	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000622	0.00237	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000622	0.00237	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000602	0.0023	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000602	0.0023	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000588	0.00224	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000574	0.00219	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000572	0.00218	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000569	0.00217	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—GNAQ—focal segmental glomerulosclerosis	0.000568	0.00217	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—FN1—focal segmental glomerulosclerosis	0.000566	0.00216	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—NOS2—focal segmental glomerulosclerosis	0.00056	0.00214	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000551	0.0021	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000551	0.0021	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000547	0.00209	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000547	0.00209	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	0.000545	0.00208	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—ALB—focal segmental glomerulosclerosis	0.000544	0.00208	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000525	0.002	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000525	0.002	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000521	0.00199	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.0005	0.00191	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.0005	0.00191	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000479	0.00183	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000478	0.00182	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	0.000471	0.0018	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—ALB—focal segmental glomerulosclerosis	0.00047	0.00179	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000467	0.00178	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000467	0.00178	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000437	0.00167	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000424	0.00162	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000424	0.00162	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000409	0.00156	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000387	0.00148	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000387	0.00148	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000386	0.00147	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000386	0.00147	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000384	0.00147	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000384	0.00147	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000371	0.00141	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000366	0.0014	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CTGF—focal segmental glomerulosclerosis	0.00036	0.00137	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.00036	0.00137	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000352	0.00134	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000352	0.00134	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.00035	0.00134	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	0.000344	0.00131	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000341	0.0013	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—FN1—focal segmental glomerulosclerosis	0.000338	0.00129	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NOS2—focal segmental glomerulosclerosis	0.000334	0.00127	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000332	0.00127	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000323	0.00123	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000323	0.00123	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000308	0.00117	CbGpPWpGaD
Alprostadil—ABCC5—Disease—LPL—focal segmental glomerulosclerosis	0.000298	0.00114	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TGFB1—focal segmental glomerulosclerosis	0.000298	0.00114	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000295	0.00113	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000295	0.00113	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000284	0.00108	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	0.000281	0.00107	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ALB—focal segmental glomerulosclerosis	0.00028	0.00107	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.00025	0.000955	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.00025	0.000955	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—LPL—focal segmental glomerulosclerosis	0.00025	0.000953	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000243	0.000927	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000243	0.000927	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000243	0.000926	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000237	0.000902	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOS2—focal segmental glomerulosclerosis	0.000233	0.000889	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.00023	0.000878	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.00023	0.000878	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AGT—focal segmental glomerulosclerosis	0.000214	0.000815	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000208	0.000793	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000208	0.000793	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SERPINE1—focal segmental glomerulosclerosis	0.000196	0.000749	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000192	0.000733	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000192	0.000733	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000181	0.000691	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TGFB1—focal segmental glomerulosclerosis	0.000177	0.000677	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ALB—focal segmental glomerulosclerosis	0.000164	0.000626	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.00016	0.00061	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.00016	0.00061	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.000149	0.00057	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TGFB1—focal segmental glomerulosclerosis	0.000124	0.000473	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000122	0.000467	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000122	0.000467	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.000101	0.000385	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.000101	0.000385	CbGpPWpGaD
